22OCT

Oxford's OMass raises $310m on foreign leads

2 min read

16:30UTC

Bain Capital Life Sciences, Forbion and Novo Holdings co-led a $310m Series C for the Oxford spinout, taking its lead drug into Phase 2.

← Back to Stryker agrees option to buy CMR Surgical Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Three foreign investors led OMass's $310m round while its British backers followed on.

OMass Therapeutics, a University of Oxford spinout, closed an oversubscribed $310m (about £230m) Series C in mid-October, co-led by Bain Capital Life Sciences of the United States, Forbion of the Netherlands and Denmark's Novo Holdings⁠¹. Every existing investor followed, including Syncona, Oxford Science Enterprises, the British Business Bank and the university itself. Syncona disclosed a £10.1m commitment.

The money takes OMS1620 into Phase 2 trials, the first tests of whether a drug works in patients, for congenital adrenal hyperplasia and Cushing's syndrome driven by adrenocorticotropic hormone (ACTH). The drug blocks the MC2 receptor, through which ACTH tells the adrenal glands to make cortisol. Bain Capital's Evan Greif joins the board.

One round of this size equals about 8% of the £2.83bn that went into all of British life sciences in the first half of the year. As leads, the three foreign investors set the terms; the Oxford spinout's existing holders, the state bank among them, followed on.

Deep Analysis

In plain English

OMass Therapeutics is a drug company that grew out of research at the University of Oxford. It has raised $310m, about £230m, from investors. The money pays for Phase 2 trials, the stage where doctors first test whether a drug actually helps patients. The drug, OMS1620, is meant for two rare hormone conditions. In both, the body makes too much of the stress hormone cortisol or related hormones, which harms health over many years. The lead investors are from the United States, the Netherlands and Denmark. British investors put money in too, but did not lead.

Deep Analysis

Root Causes

Phase 2 trials for rare endocrine disorders cost far more than British specialist funds usually write in a single round. That gap means the price-setting cheque comes from American and continental investors such as Bain Capital Life Sciences, Forbion and Novo Holdings, which run funds large enough to lead.

OMass Therapeutics' science also fits a market that pays well. Congenital adrenal hyperplasia patients currently rely on lifelong high-dose steroids, so a drug that blocks the MC2 receptor directly would compete in a disease area where pharmaceutical buyers have already shown interest.

What could happen next?

Consequence
A syndicate with crossover funds makes a public listing the likeliest next financing step for OMass Therapeutics.
Risk
A failed Phase 2 readout in congenital adrenal hyperplasia would remove most of the value this round prices in.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Immunocore, another Oxford spinout, raised about $320m privately in 2015, then the largest private financing for a European biotech, and listed on Nasdaq in February 2021. A record private round led to an American listing, not a London one.

Counter-parallel: Cambridge antibody company Kymab took the trade-sale route instead: Sanofi bought it in 2021 for $1.1bn upfront plus up to $350m in milestones, before any public listing.

Syncona, which is listed in London, disclosed a £10.1m commitment, according to RTTNews' report of its announcement. That figure is a small fraction of the $310m round, so the London-listed holder's exposure grows in money but shrinks in share.

The board seats show where control moves: Evan Greif of Bain Capital Life Sciences takes a full seat, while Novo Holdings' Max Klement and SV Health's Ali Jazayeri take observer seats, as Fierce Biotech reported.

Consensus view: Fierce Biotech framed the round around OMass Therapeutics' ambition to become "Britain's Big Biotech", and the syndicate supports that reading: Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences came in as new names beside the three co-leads, a mix of crossover and specialist funds that usually appears a year or two before a public listing.

Counter-view: The BioIndustry Association's first-half figures with Frazier & Deeter showed ten raises taking 75.2% of the £2.83bn that went into UK life sciences. On that evidence one more very large round deepens concentration at the top while the median British biotech round stays near £0.6m.

Key tension: Whether British holders such as Syncona and Oxford Science Enterprises keep a meaningful share as OMS1620 moves through Phase 2, or are diluted by each foreign-led round until the price is set entirely abroad.

Sources:Fierce Biotech

Mentions:Bain Capital Life Sciences →Forbion →Novo Holdings →Syncona →Oxford Science Enterprises →British Business Bank →University of Oxford →Evan Greif →OMS1620 →BioIndustry Association →Frazier & Deeter →Nasdaq →Cambridge →Denmark →London →United States →Netherlands →OMass Therapeutics →

First Reported In

Update #16 · Stryker agrees option to buy CMR Surgical

Fierce Biotech· 22 Oct 2026

Read original →

Causes and effects

Caused by

Ten raises took 75.2% of life sciences

OMass Therapeutics' round equals about 8% of first-half UK life-sciences funding.

Occurred 10 Sept 2026

Read story →

This Event

Oxford's OMass raises $310m on foreign leads

A single British biotech round worth about 8% of the sector's first-half funding was led from abroad.

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.